Synovus Financial Corp Has $39.10 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Synovus Financial Corp reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,246 shares of the company's stock after selling 14,318 shares during the quarter. Synovus Financial Corp's holdings in Johnson & Johnson were worth $39,097,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in JNJ. Innealta Capital LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at $27,000. Highline Wealth Partners LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $31,000. RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after acquiring an additional 91 shares during the last quarter. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson during the third quarter worth approximately $40,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on JNJ shares. Royal Bank of Canada increased their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Morgan Stanley increased their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $174.73.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $0.69 during trading on Friday, reaching $146.93. 5,631,783 shares of the company's stock were exchanged, compared to its average volume of 7,108,204. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a market cap of $353.75 billion, a P/E ratio of 21.16, a PEG ratio of 2.52 and a beta of 0.51. The firm's 50-day moving average price is $157.01 and its 200 day moving average price is $156.28.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.66 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. The ex-dividend date was Tuesday, November 26th. Johnson & Johnson's dividend payout ratio (DPR) is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.